Form 4: Vyne Therapeutics Director Patrick G. LePore Acquires 15,000 Shares

Vyne Therapeutics director Patrick G. LePore purchased 15,000 shares of common stock at an average price of $2.92 on January 15, 2025.

Summary

• Patrick G. LePore, a director at Vyne Therapeutics, acquired 15,000 shares of the company's common stock on January 15, 2025.
• The shares were purchased at a weighted average price of $2.92 per share.
• The purchases were made in multiple transactions with prices ranging from $2.8776 to $2.9836.
• Following the transaction, Mr. LePore directly owns 51,472 shares of Vyne Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it reports a routine insider transaction. It is neither positive nor negative for the company's outlook.

Positives

• The director's purchase of shares indicates confidence in the company's future prospects.
• The purchase increases the director's stake in the company, aligning his interests with those of other shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US.
• The transaction is typical for directors and officers who are acquiring or disposing of shares in their company.
• The level of detail provided is consistent with SEC requirements for insider trading disclosures.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder confidence due to the director's increased investment.

Key Dates

Keywords

Vyne Therapeutics, insider trading, stock purchase, Patrick G. LePore, director, common stock, share acquisition